Sensei Biotherapeutics (NASDAQ:FTH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sensei Biotherapeutics (NASDAQ:FTH) from a strong sell rating to a sell rating in a report issued on Saturday.

Several other equities research analysts also recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Leerink Partners initiated coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. HC Wainwright started coverage on Sensei Biotherapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $60.00 price target on the stock. Finally, Citizens Jmp started coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $54.90.

Sensei Biotherapeutics Trading Up 17.1%

Shares of FTH stock opened at $28.57 on Friday. The firm has a market capitalization of $38.28 million, a PE ratio of -0.20 and a beta of -0.25. Sensei Biotherapeutics has a 52 week low of $7.21 and a 52 week high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, equities analysts expect that Sensei Biotherapeutics will post -13.18 earnings per share for the current year.

Insider Buying and Selling at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the transaction, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brian C. Stephenson bought 5,000 shares of Sensei Biotherapeutics stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the purchase, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. The trade was a 11.99% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 49,494 shares of company stock worth $1,188,822 in the last 90 days. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC bought a new position in Sensei Biotherapeutics during the 1st quarter valued at $22,758,000. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth about $4,188,000. Finally, Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares during the last quarter. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.